News Orphazyme A/S

Equities

Delayed Nasdaq Copenhagen Other stock markets 08:59:03 29/04/2024 BST			5-day change	1st Jan Change
976.8 ^DKK	-10.39%		-2.81%	-26.56%

03-27	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-04	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

STALICLA Appoints Dr. Thomas Blaettler, MD	04-12	AQ
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
FDA Extends Review of Zevra's Arimoclomol by Three Months	03-04	DJ
BioStock: Comments from Orphazyme on the investment in CombiGene	03-04	AQ
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	02-21	AQ
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	02-20	CI
Zevra Therapeutics Refiles Arimoclomol Application With FDA	12-27	DJ
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	10/10/23	AQ
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	28/09/23	AQ
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	12/09/23	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	12/09/23	CI
Change in management	30/05/23	GL
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	30/05/23	CI
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO	30/05/23	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	30/05/23	CI
Major shareholder announcement	19/05/23	GL
Major shareholder announcement	17/05/23	GL
Resolutions passed at the Annual General Meeting	17/05/23	GL
Changes to the Board of Directors	17/05/23	AQ
Changes to the Board of Directors	17/05/23	GL

No results for this search